Please login to the form below

Not currently logged in
Email:
Password:

Biovitrum

This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP also gave positive opinions to: a new maintenance indication for AstraZeneca and Merck &Co’s PARP inhibitor Lynparza (olaparib) in ovarian cancer; the use of Swedish orphan Biovitrum’s

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Sobi poaches Pfizer’s Fredrick Wetterlundh Sobi poaches Pfizer’s Fredrick Wetterlundh

    Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team.

  • Mereo BioPharma appoints head of patient access and commercial planning Mereo BioPharma appoints head of patient access and commercial planning

    Most recently, Hughes-Wilson served on the executive leadership team as chief patient access officer and senior vice president access and external affairs at Swedish Orphan Biovitrum (Sobi), a speciality healthcare

  • Sobi appoints Norbert Oppitz SVP, speciality care Sobi appoints Norbert Oppitz SVP, speciality care

    Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.

  • Bo Jesper Hansen to step down as chairman of Sobi Bo Jesper Hansen to step down as chairman of Sobi

    Sobi's Bo Jesper Hansen is to step down as chairman of the board, a role he has held since the merger of Biovitrum and Swedish Orphan International in 2010. ... He has also served as a member of several firms' board of directors, including Alere,

  • GSK appoints rare diseases research head GSK appoints rare diseases research head

    GSK appoints rare diseases research head. Birgitte Volck moves to the company from Swedish Ophan Biovitrum. ... She will join GSK after working her six months notice at Swedish Ophan Biovitrum (Sobi), which she joined four years ago and where she served

More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics